Eric Jonasch, MD
M.D. Anderson Cancer Center · ejonasch@mdanderson.org
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Eric Jonasch, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 00:07 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT07401875 · A Phase 1b Study of HC-7366, an Agonist of ISR With Immunotherapy in Kidney Cancer (SHARK)M.D. Anderson Cancer Center · recruiting · Phase 1b, HC-7366, SHARK · principal investigator
- Ph2NCT07187778 · Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma (BLAZE)M.D. Anderson Cancer Center · recruiting · Clear Cell Renal Cell Carcinoma · principal investigator
- Ph2NCT07023432 · Belzutifan's Role in Active Surveillance Versus Treatment for Indolentmetastatic Clear Cell Renal Ccell Carcinoma (BRAVE-RCC)M.D. Anderson Cancer Center · recruiting · Active Surveillance, Clear Cell Renal Cell Carcinoma · principal investigator
- Ph2NCT07011849 · Study of Lenvatinib Plus Pembrolizumab in IO Refractory mRCC Patients With Brain MetastasesM.D. Anderson Cancer Center · withdrawn · Renal Cell Carcinoma, Brain Metastasis · principal investigator
- Ph2NCT06708949 · A Randomized Phase 2 Trial of Nivolumab, Relatlimab Plus Ipilimumab vs. Nivolumab Plus Ipilimumab in First-line Advanced Renal Cell Carcinoma (RCC)M.D. Anderson Cancer Center · active not recruiting · Renal Cell Carcinoma, Clear Cell · principal investigator
- Ph2NCT06284564 · A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC)M.D. Anderson Cancer Center · active not recruiting · Metastatic Renal Cell Carcinoma · principal investigator
- N/ANCT05955014 · Data Collection Protocol for Patients With Von Hippel Lindau DiseaseM.D. Anderson Cancer Center · recruiting · Von Hippel Lindau Disease · principal investigator
- Ph1/Ph2NCT05663710 · Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCCM.D. Anderson Cancer Center · recruiting · Advanced Cancer, Clear Cell Renal Cell Carcinoma · principal investigator
- Ph1/Ph2NCT05501054 · Phase 1b/2 Trial of Ipilimumab, Nivolumab, and Ciforadenant (Adenosine A2a Receptor Antagonist) in First-line Advanced Renal Cell Carcinoma.M.D. Anderson Cancer Center · active not recruiting · Renal Cell Carcinoma · principal investigator
- Ph2NCT02060370 · Sunitinib Scheduling in Metastatic Renal Cell Carcinoma (mRCC)M.D. Anderson Cancer Center · completed · Genitourinary Cancer, Kidney Cancer · principal investigator
- Ph2NCT01775930 · Carfilzomib in Refractory Renal Cell Carcinoma (RCC)M.D. Anderson Cancer Center · completed · Kidney Cancer · principal investigator
- Ph2NCT01266070 · TKI 258 in Von Hippel-Lindau Syndrome (VHL)M.D. Anderson Cancer Center · terminated · Von Hippel-Lindau Syndrome · principal investigator
- Ph2NCT00715442 · Pre-Surgical Sutent in Renal Cell Carcinoma (RCC)M.D. Anderson Cancer Center · active not recruiting · Renal Cell Carcinoma · principal investigator
- Ph2NCT00330564 · Evaluation of Sunitinib Malate in Patients With Von Hippel-Lindau Syndrome (VHL) Who Have VHL Lesions to FollowM.D. Anderson Cancer Center · terminated · Von Hippel-Lindau Syndrome, Renal Cell Carcinoma, Hemangioblastoma · principal investigator
- Ph2NCT00113217 · Neoadjuvant Clinical Trial to Evaluate the Efficacy of Bevacizumab for Renal Cell CarcinomaM.D. Anderson Cancer Center · completed · Renal Cell Carcinoma, Kidney Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 00:07 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.